Navigation Links
Raptor Pharmaceutical Corp. Announces Publication of Results from Phase 2a Trial of DR Cysteamine for Treatment of Cystinosis
Date:1/11/2010

(<2 nmol half-cystine/mg protein) in subjects with cystinosis. Results also indicated that the prototype DR Cysteamine effectively maintained trough WBC cystine levels within a satisfactory range when patients received approximately 60% of the previous total daily dose of IR Cysteamine.

Dr. Dohil stated, "We are seeking to improve tolerability and reduce dosing frequency requirements of IR Cysteamine which have been documented challenges for cystinosis patients, leading to widely reported instances of poor treatment compliance. We believe the results of the Phase 2a study bring us significantly closer to a potential treatment solution for cystinosis patients. The results from our trial indicate prototype delayed-release cysteamine formulation lead to improved tolerability and efficacy when administered twice-daily and at a lower total daily dose than IR Cysteamine. Based on these results, I believe that Raptor's final DR Cysteamine formulation has the potential to improve compliance and long-term treatment outcomes for cystinosis patients."

Based on these Phase 2a results, Raptor conducted a Phase 2b clinical trial using its final commercial formulation of DR Cysteamine and recently announced the following top-line Phase 2b results: DR Cysteamine demonstrated improved tolerability and the potential to reduce total daily dosage and administration frequency compared to IR Cysteamine.

  • Pharmacokinetic evaluation showed that DR Cysteamine had a terminal half-life more than three times longer than the terminal half-life of IR Cysteamine.
  • Twice-daily DR Cysteamine may achieve the same pharmacodynamic result while using a total daily dose 30% lower than IR Cysteamine administered four times daily.
  • No adverse events recorded during the clinical trial were determined by the principal investigator to be possibly or probably related to DR Cysteamine. Nine adverse events recorded in the clinical trial were determined to
    '/>"/>

SOURCE Raptor Pharmaceutical Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Raptor Pharmaceuticals Provides Update of Product Programs
2. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
3. Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease
4. Raptor Pharmaceuticals Announces Phase 2a Clinical Trial Initiation in Non-Alcoholic Steatohepatitis (NASH)
5. Raptor Pharmaceuticals Provides Update on Targeting Platforms
6. Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire dAngers for Phase II Clinical Trial in Huntingtons Disease
7. Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program
8. Raptor Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2a Clinical Trial in Non-Alcoholic Steatohepatitis (NASH)
9. Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer
10. Raptor Pharmaceuticals Receives Notices of Allowance for Two NeuroTrans(TM) Patent Applications
11. Raptor Pharmaceuticals Corp. and TorreyPines Complete Merger
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... 23, 2014  SI-BONE, Inc., a medical device company ... ® a minimally invasive surgical (MIS) device indicated ... that the U.S. Patent and Trademark Office has awarded ... for the fixation and fusion of bone.  This newly ... tapered distal end that may be placed from one bone across ...
(Date:9/23/2014)... Sept. 23, 2014 Report Details ... you trends, R&D and predicted revenues Do you ... Now get the latest analysis for those cancer ... opportunities and revenue forecasts. Visiongain,s new report ... kinase inhibition and related technology. There avoid missing ...
(Date:9/23/2014)... , Sept. 23, 2014 EnzymeBioSystems (OTCBB: ... along with the process of evaluating an enzyme ... in fighting tumors. In an effort to evaluate this ... with various contract research organizations to enlist their ... the use of an antitumor natural product called ...
Breaking Medicine Technology:SI-BONE, Inc. Strengthens Patent Portfolio with the U.S. Patent and Trademark Office's Issuance of Threaded, Fenestrated Implant Method Patent 2SI-BONE, Inc. Strengthens Patent Portfolio with the U.S. Patent and Trademark Office's Issuance of Threaded, Fenestrated Implant Method Patent 3Kinase Inhibitors for Treating Cancer: Industry Analysis, R&D Trends and World Market Forecasts 2014-2024 2Kinase Inhibitors for Treating Cancer: Industry Analysis, R&D Trends and World Market Forecasts 2014-2024 3Kinase Inhibitors for Treating Cancer: Industry Analysis, R&D Trends and World Market Forecasts 2014-2024 4Kinase Inhibitors for Treating Cancer: Industry Analysis, R&D Trends and World Market Forecasts 2014-2024 5EnzymeBioSystems Announces Progress with an Enzyme Compound 2
... today reported financial results for the third quarter ended,September ... Novavax reported a net loss of $9.0 million, or ... $5.0 million net loss, or the,equivalent of $0.08 loss ... For the nine months ended September 30, 2007, the ...
... Allos,Therapeutics, Inc. (Nasdaq: ALTH ) today announced ... non-randomized, open-label, multi-center dose,escalation study of the Company,s ... tumors or non-Hodgkin,s lymphoma (NHL). "We are ... said Pablo,J. Cagnoni, M.D., Chief Medical Officer of ...
Cached Medicine Technology:Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs 2Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs 3Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs 4Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs 5Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs 6Allos Therapeutics Initiates Study of RH1 in Patients with Advanced Solid Tumors or non-Hodgkin's Lymphoma 2Allos Therapeutics Initiates Study of RH1 in Patients with Advanced Solid Tumors or non-Hodgkin's Lymphoma 3Allos Therapeutics Initiates Study of RH1 in Patients with Advanced Solid Tumors or non-Hodgkin's Lymphoma 4
(Date:9/23/2014)... The inaugural single day event in ... New Otani Tokyo Gardens in Tokyo. Clinical data scientists will ... validation. , The second single day event in China ... in Shanghai. The clinical data scientists attending this event will ... and listings, which display data collected in clinical studies and ...
(Date:9/23/2014)... (PRWEB) September 23, 2014 "The primary purpose ... control," said an inventor from Sacramento, Ca.. "Call lights are ... or left hanging on the IV pole out of the ... the nurse call device whenever they need it, I created ... effectively position the nurse call device within easy reach. The ...
(Date:9/23/2014)... 2014 From first-hand experience, Matthew O'Farrell ... and how it can be treated. , A medically ... in 2006. His platoon sustained multiple attacks resulting in ... diagnosed with combat-related PTSD and honorably discharged from the ... I had distanced myself from my friends and family,” ...
(Date:9/23/2014)... HealthDay Reporter TUESDAY, Sept. 23, 2014 (HealthDay ... providing better care, not more care, ... A new report suggests that,s the direction the ... IMS Institute for Healthcare Informatics in Parsippany, N.J., identifies 10 ... delivery of health care and use of medicines over the ...
(Date:9/23/2014)... What information do patients need ... Forum (NQF) released a report ( http://bit.ly/1DwekE9 ), ... infographic ( http://bit.ly/1tX3lzA ) resulting from an in-depth ... patients define affordability, and what information and changes ... possible healthcare at the lowest possible cost. ...
Breaking Medicine News(10 mins):Health News:PhUSE Further Expands its Global Community Into the Asian Region 2Health News:Virtual Reality software to help treat PTSD 2Health News:Virtual Reality software to help treat PTSD 3Health News:Report Identifies Game Changers for U.S. Health Care 2Health News:Report Identifies Game Changers for U.S. Health Care 3Health News:Finding Affordable Care: Asking the Right Question is Key 2
... consumption dropped, study found , FRIDAY, June 18 (HealthDay ... may reduce consumption and help lower levels of obesity ... suggests. , Researchers examined what happened during a time ... in Boston increased the price of regular soft drinks ...
... , ... Life sell an extensive range of vitamins supplements and nutritional supplements by top manufacturers ... ... Established in 1999, Vitamins for Life (vitaminsforlife.co.uk) supplies practitioner-grade nutritional supplements that ...
... 2010: Systemic Lupus Erythematosus (SLE) patients from Brazil ... that their rheumatic conditions negatively affect their emotional ... today at EULAR 2010, the Annual Congress of ... Furthermore, findings of the French study specifically revealed ...
... The effects of Systemic Lupus Erythematosus (SLE) may differ ... results of a new study presented today at EULAR ... Rheumatism in Rome, Italy. In particular, the study reinforced ... European subpopulations. Results from a Europe-wide study, involving ...
... Kids Bento ... , ... 18, 2010 -- School’s about to start and so is the mad morning scramble of ... kids’ bento boxes , from Laptop Lunches. They’re ideal for packing fun, wholesome, ...
... ... 360 Degree Guarantee and provide consumers with coverage that extends past the original manufacturer labor ... standard warranty. , ... 18, 2010 -- Treadmill Doctor has announced the introduction of their new 360 ...
Cached Medicine News:Health News:People May Skip Soft Drinks Rather Than Pay More 2Health News:Natural Health Online Retailer VitaminsForLife.co.uk Expands Inventory to Meet UK Demands 2Health News:Natural Health Online Retailer VitaminsForLife.co.uk Expands Inventory to Meet UK Demands 3Health News:Sex lives of patients are negatively affected by rheumatoid arthritis and SLE 2Health News:Sex lives of patients are negatively affected by rheumatoid arthritis and SLE 3Health News:Kids' Lunchboxes Go Bento for Easy Back to School Lunch Making, Thanks to Laptop Lunches 2Health News:Treadmill Doctor 360 Degree Guarantee Extended Service Plans 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: